Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma

Hepatitis B virus (HBV) reactivation is well documented in individuals with cancer who receive certain cytotoxic or immunosuppressive therapies including rituximab treatment. As a general rule, the risk is greatest upon withdrawal of chemotherapy. The risk ranges from approximately 20 to 50% among H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shiba, Satoshi, Kondo, Shunsuke, Ueno, Hideki, Morizane, Chigusa, Ikeda, Masafumi, Okusaka, Takuji
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2012
Matèries:
September, 2012
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3492963/
https://ncbi.nlm.nih.gov/pubmed/23139664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000342913
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars